Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 124 articles:
HTML format



Single Articles


    September 2025
  1. XU X, Zhang C, Wang G, Dong B, et al
    Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC.
    J Clin Endocrinol Metab. 2025;110:e3245-e3251.
    PubMed     Abstract available


    August 2025
  2. CHO YY, Ahn SH, Kim M, Lee EK, et al
    TSH Cut-Offs and Recurrence Risk in Differentiated Thyroid Carcinomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025 Aug 14:dgaf463. doi: 10.1210.
    PubMed     Abstract available


  3. BILGIN C, Hibbert R, Oztepe F, Sfeir JG, et al
    Percutaneous Ablation of Parathyroid Adenomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025;110:e3150-e3162.
    PubMed     Abstract available


    June 2025
  4. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Jun 4:dgaf326. doi: 10.1210.
    PubMed     Abstract available


    May 2025
  5. FRICH PS, Sigstad E, Berstad AE, Opsahl EM, et al
    Ethanol Ablation of Metastatic Lymph Nodes in Patients with Papillary Thyroid Carcinoma - Predictors of Clinical Outcome.
    J Clin Endocrinol Metab. 2025 May 23:dgaf298. doi: 10.1210.
    PubMed     Abstract available


    March 2025
  6. SHARIQ OA, Waguespack SG, Hamidi S, Kensing BC, et al
    Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Mar 19:dgaf089. doi: 10.1210.
    PubMed     Abstract available


  7. SIMONDS WF, Li Y, Jha S
    Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2025;110:931-939.
    PubMed     Abstract available


    February 2025
  8. SCAPPATICCIO L, Di Martino N, Ferrazzano P, Maiorino MI, et al
    Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules: A Systematic Review of Literature and Meta-analysis.
    J Clin Endocrinol Metab. 2025 Feb 20:dgaf108. doi: 10.1210.
    PubMed     Abstract available


  9. GOLDFARB M, Bustos MA, Moon J, Jackson K, et al
    Pilot Study of Plasma miRNA Signature Panel for Differentiating Single vs Multiglandular Parathyroid Disease.
    J Clin Endocrinol Metab. 2025;110:758-770.
    PubMed     Abstract available


  10. LAI ST, Bauer AJ
    Approach to the Pediatric Patient with Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Feb 13:dgaf090. doi: 10.1210.
    PubMed     Abstract available


  11. ZHOU J, Li D, Ren J, Huang C, et al
    Machine Learning: A Multicentre Study on Predicting Lateral Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Feb 8:dgaf070. doi: 10.1210.
    PubMed     Abstract available


  12. WANG L, Zhang L, Ma R, Zhang Y, et al
    Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth.
    J Clin Endocrinol Metab. 2025 Feb 5:dgaf053. doi: 10.1210.
    PubMed     Abstract available


  13. CIRELLO V, Colombo C, Tosi D, Manzo A, et al
    TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Feb 1:dgaf056. doi: 10.1210.
    PubMed     Abstract available


    January 2025
  14. TELITI M, Chytiris S, Coperchini F, Cerutti M, et al
    The natural history of cytologically low-risk indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf052. doi: 10.1210.
    PubMed     Abstract available


  15. LI Y, Simonds WF, Chen H
    A Comparative Genomic Analysis of Parathyroid Adenomas and Carcinomas Harboring Heterozygous Germline CDC73 Mutations.
    J Clin Endocrinol Metab. 2025;110:429-440.
    PubMed     Abstract available


  16. NAKAI T, Horiuchi K, Okamoto T
    Predicting Tumor Volume in Primary Hyperparathyroidism From Preoperative Clinical Data.
    J Clin Endocrinol Metab. 2025;110:e391-e396.
    PubMed     Abstract available


  17. SONG JX, Dong YQ, Han RL, Xie J, et al
    PI3K/AKT/mTOR Activation is Associated with Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
    J Clin Endocrinol Metab. 2025 Jan 20:dgaf042. doi: 10.1210.
    PubMed     Abstract available


  18. ROBENSHTOK E, Bachar G, Ritter A
    Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
    J Clin Endocrinol Metab. 2025 Jan 2:dgae903. doi: 10.1210.
    PubMed     Abstract available


    November 2024
  19. CHEN Z, Sun W, Fei M, Qian K, et al
    Clinical and Sonographic Differences between RET Fusion-Positive and BRAFV600E in Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae803. doi: 10.1210.
    PubMed     Abstract available


  20. SCHUMM MA, Nikiforov YE, Nikiforova MN, Wald AI, et al
    Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Nov 14:dgae774. doi: 10.1210.
    PubMed     Abstract available



  21. Correction to: "Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics".
    J Clin Endocrinol Metab. 2024 Nov 1:dgae756. doi: 10.1210.
    PubMed    


    October 2024
  22. MENG L, Li H, Fu Y, Yu D, et al
    Somatic DICER1-Mutant Benign Thyroid Nodules in Adults: A Group of Follicular Nodular Disease With Continuous Growth.
    J Clin Endocrinol Metab. 2024 Oct 28:dgae750. doi: 10.1210.
    PubMed     Abstract available


  23. PARVATHAREDDY SK, Siraj AK, Qadri Z, Siraj N, et al
    The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 18:dgae740. doi: 10.1210.
    PubMed     Abstract available



  24. Correction to: "Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine".
    J Clin Endocrinol Metab. 2024 Oct 16:dgae717. doi: 10.1210.
    PubMed    


  25. BEHAIRY N, Leonardi AJ, Gubbi S, Kumari S, et al
    Tumor Volume Doubling Time of Less Than One Year is Associated with a Higher Risk of Death from Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 16:dgae733. doi: 10.1210.
    PubMed     Abstract available


  26. KELLY CA, Sipos JA
    Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae722. doi: 10.1210.
    PubMed     Abstract available


  27. LEE S, Antunez AG, Sinco B, Saucke MC, et al
    Cancer-related Fear and Worry in Patients with Low-Risk Thyroid Cancer: A Longitudinal Cohort Study.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae688. doi: 10.1210.
    PubMed     Abstract available


  28. HSU YC, Kuo CY, Chien MN, Jhuang JY, et al
    Overexpression of NR1D1 portends disease recurrence in thyroid cancer.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae687. doi: 10.1210.
    PubMed     Abstract available


  29. MEHANNA H, Nankivell P, Boelaert K, Woolley R, et al
    Diagnostic performance of ultrasound vs. ultrasound-guided FNAc in thyroid nodules: data from the ElaTION trial.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae682. doi: 10.1210.
    PubMed     Abstract available


  30. ROTONDI M, Endo M, Teliti M, Crescenzi A, et al
    Beyond malignancy risk stratification: FNAC report anticipates thyroid cancer staging. Insights from recent studies.
    J Clin Endocrinol Metab. 2024 Oct 1:dgae675. doi: 10.1210.
    PubMed     Abstract available


    September 2024
  31. MORETTI S, Mandarano M, Menicali E, Guzzetti M, et al
    Wnt/B-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer.
    J Clin Endocrinol Metab. 2024 Sep 27:dgae667. doi: 10.1210.
    PubMed     Abstract available


  32. XU B, Baine MK, Jungbluth A, Alabkaa A, et al
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Sep 26:dgae672. doi: 10.1210.
    PubMed     Abstract available


  33. ZHANG Y, Zhang X, Lin L, Xing M, et al
    Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae617. doi: 10.1210.
    PubMed     Abstract available


  34. MACIEL AAW, Danilovic DLS, Soares IC, Freitas TC, et al
    Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae653. doi: 10.1210.
    PubMed     Abstract available


    August 2024
  35. YUAN J, Chen Z, Zhang J, Chen X, et al
    Preoperative Serum Lipids as Novel Predictors of Survival in 3575 Papillary Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae601. doi: 10.1210.
    PubMed     Abstract available


  36. MOOIJ CF, Zwaveling-Soonawala N, Hillebrand JJ, van Trotsenburg ASP, et al
    Approach to the Patient: Challenging Cases of Pediatric Thyrotoxicosis.
    J Clin Endocrinol Metab. 2024 Aug 27:dgae592. doi: 10.1210.
    PubMed     Abstract available


  37. RAMONE T, Ghirri A, Prete A, Matrone A, et al
    Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae575. doi: 10.1210.
    PubMed     Abstract available


  38. XU Y, Gao J, Wang N, Zedenius J, et al
    BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae589. doi: 10.1210.
    PubMed     Abstract available


  39. STEGENGA MT, Oudijk L, van Velsen EFS, Peeters RP, et al
    Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
    J Clin Endocrinol Metab. 2024 Aug 21:dgae581. doi: 10.1210.
    PubMed     Abstract available


  40. CASTELLANOS LE, Zafereo ME, Sturgis EM, Wang JR, et al
    Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine.
    J Clin Endocrinol Metab. 2024 Aug 20:dgae576. doi: 10.1210.
    PubMed     Abstract available


  41. GRANI G, D'Elia S, Puxeddu E, Morelli S, et al
    Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae559. doi: 10.1210.
    PubMed     Abstract available


  42. IYER PC, Dadu R, Barque A, Zanelli C, et al
    Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
    J Clin Endocrinol Metab. 2024;109:2269-2273.
    PubMed     Abstract available


  43. LI G, Ye Z, Wei T, Zhu J, et al
    Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC.
    J Clin Endocrinol Metab. 2024;109:2294-2305.
    PubMed     Abstract available


  44. ENDO M, Peng J, Nabhan FA, Brock P, et al
    Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules.
    J Clin Endocrinol Metab. 2024;109:2317-2324.
    PubMed     Abstract available


  45. KONDA B, Sherman EJ, Massarelli E, Nieva J, et al
    Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210.
    PubMed     Abstract available


  46. GHOSH R, Auh S, Gubbi S, Veeraraghavan P, et al
    Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Aug 8:dgae537. doi: 10.1210.
    PubMed     Abstract available


  47. WANG JR, Zafereo ME, Cabanillas ME, Wu CC, et al
    The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Aug 1:dgae532. doi: 10.1210.
    PubMed     Abstract available


    July 2024
  48. FENG J, Wu C, Shen F, Cai W, et al
    Second Primary Differentiated Thyroid Carcinoma in Adult Cancer Survivors: A SEER Database Analysis.
    J Clin Endocrinol Metab. 2024 Jul 24:dgae501. doi: 10.1210.
    PubMed     Abstract available


  49. WANG H, Li Q, Tian T, Liu B, et al
    Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Jul 9:dgae465. doi: 10.1210.
    PubMed     Abstract available


  50. JING R, Wu N, Wu Y, Zhang Q, et al
    Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.
    J Clin Endocrinol Metab. 2024 Jul 6:dgae454. doi: 10.1210.
    PubMed     Abstract available



  51. Correction to: "TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Jul 1:dgae442. doi: 10.1210.
    PubMed    


    June 2024
  52. SEHGAL K, Serritella A, Liu M, ONeill A, et al
    A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Jun 29:dgae443. doi: 10.1210.
    PubMed     Abstract available


  53. PARDI E, Poma AM, Torregrossa L, Pierotti L, et al
    Whole-exome sequencing of atypical parathyroid tumors detects novel and common genes linked to parathyroid tumorigenesis.
    J Clin Endocrinol Metab. 2024 Jun 28:dgae441. doi: 10.1210.
    PubMed     Abstract available


  54. WILLIAMS MD, Liu Z, Rossi ED, Agarwal S, et al
    Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
    J Clin Endocrinol Metab. 2024 Jun 14:dgae354. doi: 10.1210.
    PubMed     Abstract available


    May 2024
  55. CAO H, Shangguan L, Zhu H, Hu C, et al
    Prognostic analysis of 131I efficacy after papillary thyroid carcinoma surgery based on CT radiomics.
    J Clin Endocrinol Metab. 2024 May 27:dgae364. doi: 10.1210.
    PubMed     Abstract available


  56. LEVESQUE F, Payne RJ, Beaudoin D, Boucher A, et al
    A Prospective Study of Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience.
    J Clin Endocrinol Metab. 2024 May 23:dgae355. doi: 10.1210.
    PubMed     Abstract available


  57. LI G, Chen W, Jiang K, Huang J, et al
    Exosome-mediated Delivery of miR-519e-5p Promotes Malignant Tumor Phenotype and CD8+ T-Cell Exhaustion in Metastatic PTC.
    J Clin Endocrinol Metab. 2024;109:1601-1617.
    PubMed     Abstract available


  58. XIAN K, Xu S, Huang H, Xing C, et al
    Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 May 15:dgae329. doi: 10.1210.
    PubMed     Abstract available


  59. ZHANG W, Lin S, Wang Z, Zhang W, et al
    Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 May 13:dgae327. doi: 10.1210.
    PubMed     Abstract available


    April 2024
  60. PETROVIC I, LoPresti J, Fatemi S, Gianoukakis A, et al
    Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA).
    J Clin Endocrinol Metab. 2024 Apr 30:dgae286. doi: 10.1210.
    PubMed     Abstract available


  61. SANT VR, Radhachandran A, Ivezic V, Lee DT, et al
    From Bench-to-Bedside: How Artificial Intelligence Is Changing Thyroid Nodule Diagnostics.
    J Clin Endocrinol Metab. 2024 Apr 29:dgae277. doi: 10.1210.
    PubMed     Abstract available


  62. ABOU AZAR S, Tobias J, Applewhite M, Angelos P, et al
    Medullary Thyroid Cancer: Single Institute Experience over Three Decades and Risk Factors for Recurrence.
    J Clin Endocrinol Metab. 2024 Apr 23:dgae279. doi: 10.1210.
    PubMed     Abstract available


  63. CHO YY, Ahn SH, Lee EK, Park YJ, et al
    Malignancy Risk of Follicular Neoplasm (Bethesda IV) With Variable Cutoffs of Tumor Size: A Systemic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2024;109:1383-1392.
    PubMed     Abstract available


  64. TODA S, Hiroshima Y, Iwasaki H, Masudo K, et al
    Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
    J Clin Endocrinol Metab. 2024 Apr 17:dgae271. doi: 10.1210.
    PubMed     Abstract available


  65. SAKO A, Matsuse M, Saenko V, Tanaka A, et al
    TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Apr 5:dgae220. doi: 10.1210.
    PubMed     Abstract available


  66. LIU CQ, Shen CK, Du YX, Li ZM, et al
    Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Apr 4:dgae214. doi: 10.1210.
    PubMed     Abstract available


    March 2024
  67. LEE-SAXTON YJ, Egan CE, Bratton BA, Thiesmeyer JW, et al
    Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
    J Clin Endocrinol Metab. 2024 Mar 30:dgae203. doi: 10.1210.
    PubMed     Abstract available


  68. MAROTTA V, Rocco D, Crocco A, Deiana MG, et al
    Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life.
    J Clin Endocrinol Metab. 2024 Mar 19:dgae181. doi: 10.1210.
    PubMed     Abstract available


  69. OHIRA T, Nagao M, Hayashi F, Shimura H, et al
    Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2024 Mar 13:dgae161. doi: 10.1210.
    PubMed     Abstract available


  70. CHEN H, Liu Y, Wang F, Sun J, et al
    MeIS: DNA methylation-based immune response signatures for thyroid nodule diagnostics.
    J Clin Endocrinol Metab. 2024 Mar 7:dgae141. doi: 10.1210.
    PubMed     Abstract available


  71. HENSLEY SG, Hu MI, Bassett RL, Ying AK, et al
    Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
    J Clin Endocrinol Metab. 2024 Mar 4:dgae133. doi: 10.1210.
    PubMed     Abstract available


    February 2024
  72. JAGANNATH S, Mayilvaganan S
    Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Feb 29:dgae117. doi: 10.1210.
    PubMed    


  73. SARKAR R, Bolel P, Kapoor A, Eliseeva E, et al
    An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.
    J Clin Endocrinol Metab. 2024 Feb 29:dgae114. doi: 10.1210.
    PubMed     Abstract available


  74. SCHOLFIELD DW, Lopez J, Eagan A, Antal Z, et al
    Response to Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?".
    J Clin Endocrinol Metab. 2024 Feb 28:dgae118. doi: 10.1210.
    PubMed    


  75. AHMADI S, Kotwal A, Bikas A, Xiang P, et al
    Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae112. doi: 10.1210.
    PubMed     Abstract available


  76. VAN DER TUIN K, Ruano D, Knijnenburg J, van der Luijt RB, et al
    Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae107. doi: 10.1210.
    PubMed     Abstract available


  77. MAINO F, Botte M, Dalmiglio C, Valerio L, et al
    Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
    J Clin Endocrinol Metab. 2024;109:722-729.
    PubMed     Abstract available


  78. STEGENGA MT, van Velsen EFS, Oudijk L, Verburg FA, et al
    Clinical and Histopathological Risk Factors for Radioactive Iodine Refractory Follicular and Oncocytic Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae084. doi: 10.1210.
    PubMed     Abstract available


  79. ALTSHULER B, Bikas A, Pappa T, Marqusee E, et al
    Non-Operative, Active Surveillance of Larger Malignant and Suspicious Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae082. doi: 10.1210.
    PubMed     Abstract available


    January 2024
  80. CONDELLO V, Poma AM, Macerola E, Vignali P, et al
    Prevalence, Molecular Landscape and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Jan 22:dgae034. doi: 10.1210.
    PubMed     Abstract available


  81. BHARADWAJ MS, Ballal S, Bal C
    Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.
    J Clin Endocrinol Metab. 2024 Jan 12:dgae024. doi: 10.1210.
    PubMed     Abstract available


  82. BUCZYNSKA A, Kosciuszko M, Sidorkiewicz I, Wiatr AA, et al
    Enhancing Angioinvasion Assessment in Papillary Thyroid Cancer via a Biomarker Panel Involving TAC, 8-OHdG and Sortilin.
    J Clin Endocrinol Metab. 2024 Jan 5:dgae007. doi: 10.1210.
    PubMed     Abstract available


    December 2023
  83. KIM BH, Ryu SR, Lee JW, Song CM, et al
    Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2023 Dec 23:dgad748. doi: 10.1210.
    PubMed     Abstract available


  84. PAPARODIS R, Livadas S, Karvounis E, Bantouna D, et al
    Elevated Preoperative TPO Ab Titers Decrease Risk for DTC in a Linear Fashion: A Retrospective Analysis of 1635 Cases.
    J Clin Endocrinol Metab. 2023;109:e347-e355.
    PubMed     Abstract available


  85. GOLDNER W
    The Role of Age in the Risk Assessment of Differentiated Thyroid Cancers.
    J Clin Endocrinol Metab. 2023 Dec 20:dgad743. doi: 10.1210.
    PubMed    


  86. LIN S, Wang Z, Xing M
    Association between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.
    J Clin Endocrinol Metab. 2023 Dec 8:dgad722. doi: 10.1210.
    PubMed     Abstract available


  87. MU Z, Zhang X, Sun D, Sun Y, et al
    Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer.
    J Clin Endocrinol Metab. 2023 Dec 7:dgad697. doi: 10.1210.
    PubMed     Abstract available


  88. LEUNG AM, Brent GA
    Pregnancy - Does Promotion of Growth Extend to Thyroid Cancer?
    J Clin Endocrinol Metab. 2023 Dec 2:dgad707. doi: 10.1210.
    PubMed    


  89. WANG Y, Zou B, Zhang Y, Zhang J, et al
    Comprehensive long-read sequencing analysis discloses the transcriptome features of Papillary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Dec 1:dgad695. doi: 10.1210.
    PubMed     Abstract available


    November 2023
  90. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Role of the degree of vascular invasion in predicting prognosis of follicular thyroid carcinoma.
    J Clin Endocrinol Metab. 2023 Nov 25:dgad689. doi: 10.1210.
    PubMed     Abstract available


  91. TORA R, Welch J, Sun J, Agarwal SK, et al
    Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2023;108:3165-3177.
    PubMed     Abstract available


  92. LIU Q, Mao L, Zhang Z, Li G, et al
    Diagnostic Efficacy of FNA-Tg in DTC Cervical LN Metastasis and its Impact Factors: A Large Retrospective Study.
    J Clin Endocrinol Metab. 2023;108:3311-3319.
    PubMed     Abstract available


  93. FALCHETTI A
    New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.
    J Clin Endocrinol Metab. 2023;108:e1751-e1752.
    PubMed    


  94. LI P, Liu Y, Wei T, Wang X, et al
    Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.
    J Clin Endocrinol Metab. 2023 Nov 15:dgad667. doi: 10.1210.
    PubMed     Abstract available


    October 2023
  95. KWON H, Han KD, Moon SJ, Park SE, et al
    Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.
    J Clin Endocrinol Metab. 2023 Oct 31:dgad575. doi: 10.1210.
    PubMed     Abstract available


  96. DAI P, Zhao W, Zheng X, Luo H, et al
    Effect of radioactive iodine therapy on cancer-specific survival of papillary thyroid cancer tall cell variant.
    J Clin Endocrinol Metab. 2023 Oct 7:dgad580. doi: 10.1210.
    PubMed     Abstract available



  97. Correction to "The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation".
    J Clin Endocrinol Metab. 2023 Oct 3:dgad573. doi: 10.1210.
    PubMed    


    September 2023
  98. PALYGA I, Rumian M, Kosel A, Albrzykowski M, et al
    The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy.
    J Clin Endocrinol Metab. 2023 Sep 28:dgad571. doi: 10.1210.
    PubMed     Abstract available


  99. XIAO WC, Li X, Shan R, Mei F, et al
    Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study.
    J Clin Endocrinol Metab. 2023 Sep 20:dgad557. doi: 10.1210.
    PubMed     Abstract available


  100. POZDEYEV N, Dighe M, Barrio M, Raeburn C, et al
    Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
    J Clin Endocrinol Metab. 2023 Sep 8:dgad530. doi: 10.1210.
    PubMed     Abstract available


  101. ILGAN S, Aydogan BI, Emer O, Anil C, et al
    Sonographic features of atypical and initially missed parathyroid adenomas: Lessons learned from a single center cohort.
    J Clin Endocrinol Metab. 2023 Sep 5:dgad527. doi: 10.1210.
    PubMed     Abstract available


    August 2023
  102. GILLIS A, Chen H, Wang TS, Dream S, et al
    Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease: a Mini- Review.
    J Clin Endocrinol Metab. 2023 Aug 30:dgad519. doi: 10.1210.
    PubMed     Abstract available


  103. HA EJ, Lee JH, Lee DH, Moon J, et al
    Artificial Intelligence Model Assisting Thyroid Nodule Diagnosis and Management: A Multicenter Diagnostic Study.
    J Clin Endocrinol Metab. 2023 Aug 25:dgad503. doi: 10.1210.
    PubMed     Abstract available


  104. JU G, Sun Y, Wang H, Zhang X, et al
    Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2023 Aug 25:dgad500. doi: 10.1210.
    PubMed     Abstract available


  105. LI H, Han R, Meng L, Sun Y, et al
    Nodal Metastases Associated with Fusion Oncogenes Are Age Dependent in Young Adult Patients with Thyroid Cancer.
    J Clin Endocrinol Metab. 2023 Aug 3:dgad458. doi: 10.1210.
    PubMed     Abstract available


    July 2023
  106. MERCADO M
    The Role of Androgen Receptors in Thyroid Cancer Biology: Beyond Sexual Dimorphism.
    J Clin Endocrinol Metab. 2023 Jul 15:dgad424. doi: 10.1210.
    PubMed    


  107. NOEL JE, Sinclair CF
    Radiofrequency Ablation for Benign Thyroid Nodules.
    J Clin Endocrinol Metab. 2023 Jul 4:dgad357. doi: 10.1210.
    PubMed     Abstract available


    June 2023
  108. YAN L, Zhen Y, Li Y, Li X, et al
    Five-year Outcome Between Radiofrequency Ablation vs. Surgery for Unilateral Multifocal Papillary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Jun 15:dgad360. doi: 10.1210.
    PubMed     Abstract available


  109. YEH MW
    The molecular landscape of thyroid nodules: Diagnostic and prognostic revelations from a large multicenter cohort.
    J Clin Endocrinol Metab. 2023 Jun 15:dgad362. doi: 10.1210.
    PubMed    


  110. SATAPATHY S, Majeed AK, Ballal S, Bal C, et al
    Differentiated thyroid cancers in young adults versus children: Clinical characteristics and ten-year follow-up outcomes.
    J Clin Endocrinol Metab. 2023 Jun 7:dgad343. doi: 10.1210.
    PubMed     Abstract available


  111. ZHOU Y, Wang Y, Zhang Z, Yin X, et al
    Male sex is not a risk factor for prognosis in postoperative thyroid cancer patients: a propensity score matching study.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad314. doi: 10.1210.
    PubMed     Abstract available


  112. BOJARSKY M, Baran JA, Halada S, Isaza A, et al
    Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated with Radioactive Iodine Therapy.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad322. doi: 10.1210.
    PubMed     Abstract available


    May 2023
  113. LIN Y, Wu ZR, Shi YP, Ding M, et al
    Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation.
    J Clin Endocrinol Metab. 2023 May 23:dgad269. doi: 10.1210.
    PubMed     Abstract available


  114. CHOU CK, Chi SY, Hung YY, Yang YC, et al
    Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness.
    J Clin Endocrinol Metab. 2023 May 23:dgad279. doi: 10.1210.
    PubMed     Abstract available


  115. ALZAHRANI AS
    Clinical use of molecular data in thyroid nodules and cancer.
    J Clin Endocrinol Metab. 2023 May 18:dgad282. doi: 10.1210.
    PubMed     Abstract available


  116. SUN Y, Sun Q, Tian J, He X, et al
    Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer.
    J Clin Endocrinol Metab. 2023 May 11:dgad264. doi: 10.1210.
    PubMed     Abstract available


    April 2023
  117. ULLMANN TM, Sosa JA
    Delay in Surgery for Papillary Thyroid Cancer: A Proxy for Lower-Quality Care?
    J Clin Endocrinol Metab. 2023 Apr 21:dgad232. doi: 10.1210.
    PubMed    


  118. CHIOSEA S, Hodak SP, Yip L, Abraham D, et al
    Molecular Profiling of 50,734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
    J Clin Endocrinol Metab. 2023 Apr 18:dgad220. doi: 10.1210.
    PubMed     Abstract available


    March 2023
  119. ALZAHRANI AS
    The risk of expanding risk stratification in thyroid cancer.
    J Clin Endocrinol Metab. 2023 Mar 29:dgad182. doi: 10.1210.
    PubMed    


  120. CHAVES N, Broekhuis JM, Fligor SC, Collins RA, et al
    Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: a SEER-Medicare Analysis.
    J Clin Endocrinol Metab. 2023 Mar 29:dgad163. doi: 10.1210.
    PubMed     Abstract available


  121. VAN VELSEN EFS, Verburg FA
    Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer - To Treat or Not To Treat.
    J Clin Endocrinol Metab. 2023 Mar 25:dgad171. doi: 10.1210.
    PubMed    


  122. KESBY N, Mechera R, Fuchs T, Papachristos A, et al
    Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Mar 25:dgad173. doi: 10.1210.
    PubMed     Abstract available


  123. NASR CE
    Can one predict long-term growth of cytologically-benign thyroid nodules?
    J Clin Endocrinol Metab. 2023 Mar 22:dgad160. doi: 10.1210.
    PubMed    


  124. JHA S, Welch J, Tora R, Lack J, et al
    Germline and somatic inactivating FLCN variants in parathyroid cancer and atypical parathyroid tumors.
    J Clin Endocrinol Metab. 2023 Mar 20:dgad136. doi: 10.1210.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.